The (Pro)renin Receptor - A Regulatory Nodal Point in Disease Networks

Heiko Funke-Kaiser*, Thomas Unger

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

Abstract

Experimental inhibition of the (pro)renin receptor [(P)RR] is a promising therapeutic strategy in different disease models ranging from cardiorenal to oncological entities. Here, we briefly review the direct protein-protein interaction partners of the (P)RR and the plethora of distinct diseases in which the (P)RR is involved. The first structural work on the (P)RR using AlphaFold, which was recently published by Ebihara et al., is the center of this mini-review since it can mechanistically link the protein-protein interaction level with the pathophysiological level. More detailed insights into the 3D structure of the (P)RR and its interaction domains might guide drug discovery on this novel target. Finally, antibody- and small molecule-based approaches to inhibit the (P)RR are shortly discussed.
Original languageEnglish
Pages (from-to)1093-1098
Number of pages6
JournalCurrent drug targets
Volume24
Issue number14
DOIs
Publication statusPublished - 25 Oct 2023

Keywords

  • (pro)renin receptor (P)RR
  • Alphafold
  • cardio-renal
  • drug target
  • oncology
  • protein-protein interaction partners

Fingerprint

Dive into the research topics of 'The (Pro)renin Receptor - A Regulatory Nodal Point in Disease Networks'. Together they form a unique fingerprint.

Cite this